Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover1
| Autor: | Keishi Hata, Seiji Fukumoto, Ryo Okazaki, Kumiko Hamano, Miho Ajima, Yoshiko Hirota, Masakazu Miura, Toshio Matsumoto, Yasuo Totsuka |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
medicine.medical_specialty
Deoxypyridinoline endocrine system diseases Bone density business.industry Endocrinology Diabetes and Metabolism Biochemistry (medical) Clinical Biochemistry Parathyroid hormone Biochemistry Bone resorption Bone remodeling chemistry.chemical_compound Endocrinology Glycemic index N-terminal telopeptide chemistry Internal medicine medicine business Glycemic |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 82:2915-2920 |
| ISSN: | 1945-7197 0021-972X |
| Popis: | Patients with poorly controlled noninsulin dependent diabetes mellitus (NIDDM) are shown to have higher bone mass. However, the influence of changes in glycemic control on bone turnover is not known. To clarify whether metabolic improvement of poorly controlled NIDDM affects bone turnover, markers for glucose, mineral, and bone metabolism were assessed before and after glycemic control for 3 weeks in 78 poorly controlled NIDDM patients with initial hemoglobin A1c over 8%. Metabolic improvement caused a reduction in urinary calcium (Ca) and phosphate (Pi) and serum 1,25(OH)2D levels, and an increase in serum Pi without changes in serum Ca or parathyroid hormone levels. Bone resorption markers, urinary deoxypyridinoline (Dpd) and type I collagen carboxy-terminal telopeptide (CTx), as well as a bone formation marker, serum bone type alkaline phosphatase (BALP), were reduced. However, another bone formation marker, serum osteocalcin (OC), was low before treatment and was elevated after treatment. The decrease in Dpd, CTx and BALP, but not the increase in OC, correlated with each other and with the improvement in glycemic indices. In conclusion, metabolic improvement of poorly controlled NIDDM decreases bone turnover within a short period. Thus, glycemic control may protect NIDDM patients from bone loss. It is possible that serum OC is affected by hyperglycemia per se, and may not correctly reflect bone turnover. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|